Skip to main content
. 2023 Aug 8;12(16):2019. doi: 10.3390/cells12162019

Figure 3.

Figure 3

Current FDA-approved treatments and proposed targets for AD. In the past few years, the FDA has approved several drugs and treatments for AD, targeting the usual culprits, namely, beta-amyloid plaques and tau tangles. The potential therapeutic targets for hypometabolism in AD include targeting the BBB and glucose transporter overexpression.